Health
Pentixapharm Announces Peer-Reviewed Phase 2 Data Back Use of PENTIXAFOR as a Superior Non-invasive PET-Diagnostic for Primary Aldosteronism
In the study, [68Ga]Ga-Pentixafor PET/CT was well tolerated and demonstrated high specificity and moderate sensitivity for identifying unilateral aldosterone-producing adenomas compared with adrenal vein sampling (AVS) and surgical outcomes The data ...
About this update from Pentixapharm Holding Ag
[{"type":"list","items":[{"val":[{"type":"text","content":"In the study, [68Ga]Ga-Pentixafor PET/CT was well tolerated and demonstrated high specificity and moderate sensitivity for identifying unilateral aldosterone-producing adenomas compared with adrenal vein sampling (AVS) and surgical outcomes","length":240,"tagName":"p"}]},{"val":[{"type":"text","content":"The data strengthens the clinical foundation for Phase 3 development and support the role of molecular imaging in guiding treatment decisions in the population with hypertension and underlying primary aldosteronism","length":214,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":454,"olType":false},{"type":"text","content":"BERLIN, DE / ACCESS Newswire / February 5, 2026 / Pentixapharm Holding AG (Frankfurt Prime Standard:PTP), an advanced clinical-stage biotech developing novel radiopharmaceuticals, today announced publication of new Phase 2 clinical data in the Journal of Nuclear Medicine demonstrating the potential of [68Ga]Ga-Pentixafor PET/CT as a non-invasive imaging tool for subtyping primary aldosteronism (PA), the leading endocrine cause of hypertension.","length":447,"tagName":"p"},{"type":"text","content":"The investigator-initiated study, funded by an Australian philanthropic foundation, the CASS Foundation, and the Medical Research Future Fund, was conducted as a prospective cohort study in Australia. It evaluated [68Ga]Ga-Pentixafor PET/CT as a potential alternative to adrenal vein sampling (AVS), the current standard of care for distinguishing unilateral aldosterone-producing adrenal adenomas from bilateral disease. AVS is invasive, resource-intensive, and available only in highly specialized centers, creating barriers to timely and accurate patient stratification.","length":573,"tagName":"p"},{"type":"text","content":"Results published online show that [68Ga]Ga-Pentixafor PET/CT demonstrated high specificity and moderate sensitivity for identifying unilateral aldosterone-producing adenomas when compared with AVS and surgical outcomes. Importantly, the imaging approach was well tolerated and strongly preferred by patients, with 28 of 29 participants indicating PET/CT as the favoured diagnostic test.","length":387,"tagName":"p"},{"type":"text","content":""These data provide evidence that molecular imaging with [68Ga]Ga-Pentixafor PET/CT can support accurate and patien...